Showing results (141-150 of 153) with videos related to
Sort By:
Pageof 16
Journal of the National Cancer Institute|December 12, 2017
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial ResultsOleg Gluz, Ulrike Nitz, Cornelia Liedtke, et al.Journal of Cellular and Molecular Medicine|October 9, 2025
The Janus Face of SPAG6: Inducing EMT in Luminal Breast Cancer Cells Amidst Widespread Expression Loss in Breast TumoursAntonio Sechi, Jolein Mijnes, Sophia Villwock, et al.JAMA Network Open|February 26, 2025
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical TrialLisa Richters, Oleg Gluz, Nana Weber-Lassalle, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2022
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast CancerUlrike A Nitz, Oleg Gluz, Sherko Kümmel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 28, 2022
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- TrialMonika Graeser, Oleg Gluz, Claudia Biehl, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2023
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP TrialNadia Harbeck, Ulrike A Nitz, Matthias Christgen, et al.The Lancet. Oncology|May 3, 2025
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trialSherko Kuemmel, Monika Graeser, Peter Schmid, et al.Breast Cancer Research : BCR|February 14, 2025
HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TNGilda Schmidt, Oleg Gluz, Matthias Christgen, et al.Cancer Discovery|April 4, 2018
E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast CancerIlirjana Bajrami, Rebecca Marlow, Marieke van de Ven, et al.European Journal of Human Genetics : EJHG|January 20, 2018
Variants in members of the cadherin-catenin complex, CDH1 and CTNND1, cause blepharocheilodontic syndromeAnneke Kievit, Federico Tessadori, Hannie Douben, et al.Pageof 16